Last reviewed · How we verify
CIT-013 high dose
CIT-013 high dose is a small molecule that targets the SGLT2 receptor.
CIT-013 high dose is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | CIT-013 high dose |
|---|---|
| Sponsor | Citryll BV |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the SGLT2 receptor, CIT-013 high dose reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and subsequent lowering of blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The exact molecular details of CIT-013 high dose's interaction with the SGLT2 receptor are not well understood.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
- Increased risk of genital yeast infections
- Increased risk of hypotension
- Increased risk of acute kidney injury
Key clinical trials
- A Study With CIT-013 in RA Patients (PHASE2)
- A Study With CIT-013 in HS Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CIT-013 high dose CI brief — competitive landscape report
- CIT-013 high dose updates RSS · CI watch RSS
- Citryll BV portfolio CI